✦ LIBER ✦

[606] COMPARISON OF PEGINTERFERON a-2a AND RIBAVIRIN FOR 12 OR 24 WEEKS IN PATIENTS WITH HCV GENOTYPE 2/3: THE NORDYNAMIC TRIAL

✍ Scribed by M. Lagging; C. Pedersen; M. Rauning Buhl; M. Farkkila; N. Langeland; K. Morch; G. Norkrans

Book ID: 117375698
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 144 KB
Volume: 46
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(07)62204-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

734 Peginterferon alpha-2a (PEGASYS) plu

734 Peginterferon alpha-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 OR 3. Final results of the accelerate trial

✍ M.L. Shiffman; S. Pappas; L. Nyberg; S. Greenbloom; A. Gibas; B. Bacons; J. Rase 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 124 KB

1418 DACLATASVIR COMBINED WITH PEGINTERF

1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY

✍ Dore, G.J.; Lawitz, E.; H'ezode, C.; Shafran, S.; Ramji, A.; Tatum, H.; Taliani, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 78 KB

[128] PEGINTERFERON o-2b AND RIBAVIRIN F

[128] PEGINTERFERON o-2b AND RIBAVIRIN FOR 14 OR 24 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 AND RAPID VIROLOGICAL RESPONSE. THE NORTH-C TRIAL

✍ O. Dalgard; K. Bjoro; H. Ring-Larsen; H. Verbaan 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 82 KB

Peginterferon-α-2a (40KD) and Ribavirin

Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C

✍ Michael von Wagner; Miriam Huber; Thomas Berg; Holger Hinrichsen; Jens Rasenack; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 173 KB

Randomized comparison of 12 or 24 weeks

Randomized comparison of 12 or 24 weeks of peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection

✍ Martin Lagging; Nina Langeland; Court Pedersen; Martti Färkkilä; Mads Rauning Bu 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 377 KB

Previous trials investigating the efficacy of treatment durations shorter than the standard of 24 weeks for chronic hepatitis C virus (HCV) genotype 2/3 infections have yielded discordant results. The aims of this investigator-initiated phase III study were to compare the efficacy of 12 or 24 weeks

[604] COMPARISON OF A SHORTENED RIBAVIRI

[604] COMPARISON OF A SHORTENED RIBAVIRIN TREATMENT VS A 24 WEEK STANDARD COMBINATION THERAPY IN HCV INFECTED PATIENTS WITH GENOTYPE 2/3

✍ B. Kallinowski; K. Stein; W. Boecher; T. Goeser; U. Spengler; R. Link; H. Klinke 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 276 KB